Back to All Combinations

KRAS G12C

Intermediate Prognosis
3.50% Prevalence Level 1 RAS Pathway
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
KRAS
Treatment Implications

First targetable KRAS! Sotorasib/adagrasib + anti-EGFR show ~30% ORR.

Recommended Treatments
Sotorasib + Panitumumab
Adagrasib + Cetuximab
Sotorasib
Adagrasib
Treatments to Avoid
Anti-EGFR monotherapy
Study References

CodeBreaK 100/101, KRYSTAL-1

Key Statistics
3.50%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Combinations extend benefit vs monotherapy.
Information

Category: RAS Pathway

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.